drTarget portfolio target-disease associations for immune system

OpenTargets offers > 27k target-disease associations from PChem targets suitable for virtual screening based in OpenTargets scores for immune diseases. See here the best scored pairs.

Target-disease associations for immune diseases.

Check best scored target-disease associations in table:

PubChemAssay	program	assayType	testedComopunds	activeCompounds	diseaseName	weightedScore	weightedEvidence
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Crohn's disease	0.66633861809884	35
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	targetBased	143816	859	Crohn's disease	0.369489609878927	8
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	targetBased	363803	1383	Crohn's disease	0.332442928560379	8
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	Crohn's disease	0.332959636528519	7
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	Crohn's disease	0.332959636528519	7
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	Crohn's disease	0.614524204063885	20
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	Crohn's disease	0.297910135217532	32
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	Crohn's disease	0.737705438254737	75
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	Crohn's disease	0.340694061111576	7
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	targetBased	325247	1021	Crohn's disease	0.379885398185413	20
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	Crohn's disease	0.325348050422973	14
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	Crohn's disease	0.325348050422973	14
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	Crohn's disease	0.606813177486441	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	Crohn's disease	0.606813177486441	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	Crohn's disease	0.606813177486441	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	Crohn's disease	0.606813177486441	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	Crohn's disease	0.606813177486441	22
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	Crohn's disease	0.606813177486441	22
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	targetBased	217454	1142	Crohn's disease	0.266249542498813	6
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	Crohn's disease	0.51331093980131	8
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	Crohn's disease	0.923073177649278	1414
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	Crohn's disease	0.5018282116886	13
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	Crohn's disease	0.5018282116886	13
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	Crohn's disease	0.424333797212919	22
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	atopic eczema	0.295300014382582	7
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	atopic eczema	0.295300014382582	7
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	atopic eczema	0.623231800016832	67
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	targetBased	324747	7988	atopic eczema	0.410445598825414	13
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	atopic eczema	0.417866746569554	23
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	atopic eczema	0.316542135854887	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	atopic eczema	0.439677534307829	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	rheumatoid arthritis	0.41826550590229	30
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	rheumatoid arthritis	0.41826550590229	30
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	rheumatoid arthritis	0.68876863655042	227
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	rheumatoid arthritis	0.408905740315506	8
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	targetBased	340696	1654	rheumatoid arthritis	0.523283731423149	34
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	rheumatoid arthritis	0.316170628682077	16
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	rheumatoid arthritis	0.316170628682077	16
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	rheumatoid arthritis	0.316170628682077	16
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	rheumatoid arthritis	0.316170628682077	16
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	rheumatoid arthritis	0.316170628682077	16
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	rheumatoid arthritis	0.316170628682077	16
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	targetBased	326022	1334	rheumatoid arthritis	0.687131196796391	53
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	rheumatoid arthritis	0.344497760009479	15
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	rheumatoid arthritis	0.518622044684266	7
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	rheumatoid arthritis	0.666736202498445	133
HTS for developing T Cell Immune Modulators	ITGAL	targetBased	326271	221	psoriasis	0.647172633973302	119
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	psoriasis	0.519072092168666	26
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	psoriasis	0.52623853206338	110
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	targetBased	324747	7988	psoriasis	0.687648482714935	222
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	psoriasis	0.339337400587504	695
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	psoriasis	0.339337400587504	695
qHTS of IL-2 Activators	IL2	targetBased	364617	238	psoriasis	0.321063444162615	207
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	psoriasis	0.368222903581623	914
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	targetBased	325247	1021	psoriasis	0.318702620448013	12
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	targetBased	304060	10600	psoriasis	0.276155592989189	65
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	pathwayBased	7671	874	psoriasis	0.276155592989189	65
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	pathwayBased	305439	16717	psoriasis	0.276155592989189	65
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	targetBased	335777	499	psoriasis	0.546229169969465	140
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	psoriasis	0.437397772906933	14
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	psoriasis	0.351463457960425	502
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	psoriasis	0.351463457960425	502
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	psoriasis	0.682247545111168	296
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	psoriasis	0.413899156141244	47
HTS for developing T Cell Immune Modulators	ITGAL	targetBased	326271	221	ulcerative colitis	0.261097385083632	9
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	targetBased	194152	1342	ulcerative colitis	0.464712841053478	21
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	ulcerative colitis	0.324962882417437	192
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	ulcerative colitis	0.324962882417437	192
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	ulcerative colitis	0.760994816046525	161
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	targetBased	363803	1383	ulcerative colitis	0.299642360244183	21
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	ulcerative colitis	0.315719626583571	30
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	targetBased	324747	7988	ulcerative colitis	0.33787439712456	74
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	ulcerative colitis	0.328488655948732	68
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	ulcerative colitis	0.446337451033987	696
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	ulcerative colitis	0.655877863539481	66
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	targetBased	363803	458	ulcerative colitis	0.518921467802981	15
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	targetBased	325247	1021	ulcerative colitis	0.257406185494847	30
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	ulcerative colitis	0.590697841480425	26
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	ulcerative colitis	0.590697841480425	26
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	ulcerative colitis	0.692888906416013	432
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	ulcerative colitis	0.692888906416013	432
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	ulcerative colitis	0.692888906416013	432
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	ulcerative colitis	0.692888906416013	432
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	ulcerative colitis	0.692888906416013	432
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	ulcerative colitis	0.692888906416013	432
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	ulcerative colitis	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	ulcerative colitis	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	ulcerative colitis	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	ulcerative colitis	0.335150295135842	483
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	ulcerative colitis	0.335150295135842	483
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	ulcerative colitis	0.328864540185122	323
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	targetBased	304060	10600	ulcerative colitis	0.385177046740896	41
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	pathwayBased	7671	874	ulcerative colitis	0.385177046740896	41
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	pathwayBased	305439	16717	ulcerative colitis	0.385177046740896	41
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	ulcerative colitis	0.30837818021927	33
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	ulcerative colitis	0.477180480331524	32
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	ulcerative colitis	0.802339118184399	318
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	ulcerative colitis	0.359123268930043	351
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	ulcerative colitis	0.359123268930043	351
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	targetBased	47480	334	ulcerative colitis	0.343824520808528	39
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	ulcerative colitis	0.644099885304213	123
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	ulcerative colitis	0.42005545401222	150
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	targetBased	358434	2554	celiac disease	0.269403932902958	14
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	ulcerative colitis	0.354954988090465	61
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	ulcerative colitis	0.494586180209997	950
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	ulcerative colitis	0.494586180209997	950
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	colitis	0.457463840244192	110
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	colitis	0.274984130748396	35
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	colitis	0.305284900636795	518
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	colitis	0.305284900636795	518
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	colitis	0.305284900636795	518
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	colitis	0.305284900636795	518
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	colitis	0.305284900636795	518
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	colitis	0.305284900636795	518
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	targetBased	304060	10600	colitis	0.29549917499103	62
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	pathwayBased	7671	874	colitis	0.29549917499103	62
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	pathwayBased	305439	16717	colitis	0.29549917499103	62
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	colitis	0.346136900375504	358
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	antiphospholipid syndrome	0.317964370558289	6
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selective compounds	targetBased	396029	13426	inflammatory bowel disease	0.276235168570378	134
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selective compounds	targetBased	395981	5516	inflammatory bowel disease	0.276235168570378	134
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	targetBased	194152	1342	inflammatory bowel disease	0.442884054302183	14
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	inflammatory bowel disease	0.577230617368294	191
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	inflammatory bowel disease	0.255444106574039	1009
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	inflammatory bowel disease	0.47424467902973	338
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	inflammatory bowel disease	0.429537177851221	1828
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	inflammatory bowel disease	0.450159732473526	26
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	inflammatory bowel disease	0.450159732473526	26
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	inflammatory bowel disease	0.539973454347842	88
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	inflammatory bowel disease	0.316933224547464	53
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	targetBased	363803	458	inflammatory bowel disease	0.429840930588652	33
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	inflammatory bowel disease	0.263404934707527	29
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	inflammatory bowel disease	0.263404934707527	29
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	inflammatory bowel disease	0.593795823724006	632
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	inflammatory bowel disease	0.593795823724006	632
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	inflammatory bowel disease	0.593795823724006	632
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	inflammatory bowel disease	0.593795823724006	632
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	inflammatory bowel disease	0.593795823724006	632
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	inflammatory bowel disease	0.593795823724006	632
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	targetBased	304060	10600	inflammatory bowel disease	0.401130853590169	81
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	pathwayBased	7671	874	inflammatory bowel disease	0.401130853590169	81
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	pathwayBased	305439	16717	inflammatory bowel disease	0.401130853590169	81
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	targetBased	369953	3080	inflammatory bowel disease	0.274356875163875	282
uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase	ALPI_inhibitors	targetBased	330392	393	inflammatory bowel disease	0.551025850997796	30
uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase	ALPI_inhibitors	targetBased	331670	664	inflammatory bowel disease	0.551025850997796	30
Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase	ALPI_activators	targetBased	195570	326	inflammatory bowel disease	0.551025850997796	30
uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase	ALPI_activators	targetBased	330392	537	inflammatory bowel disease	0.551025850997796	30
uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase	ALPI_activators	targetBased	331670	785	inflammatory bowel disease	0.551025850997796	30
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	inflammatory bowel disease	0.532992751133878	89
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	inflammatory bowel disease	0.703692814590368	1872
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	inflammatory bowel disease	0.426166728756354	892
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	inflammatory bowel disease	0.426166728756354	892
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	targetBased	47480	334	inflammatory bowel disease	0.32166348562018	32
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	inflammatory bowel disease	0.28469229931646	111
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	targetBased	325247	1021	inflammatory bowel disease	0.400162717303332	25
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	chronic progressive multiple sclerosis	0.538635520397193	20
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	seasonal allergic rhinitis	0.448820053202874	8
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	seasonal allergic rhinitis	0.448820053202874	8
qHTS of IL-2 Activators	IL2	targetBased	364617	238	seasonal allergic rhinitis	0.332747471857003	11
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	seasonal allergic rhinitis	0.43297757656177	17
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	seasonal allergic rhinitis	0.620287278383327	14
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	seasonal allergic rhinitis	0.620287278383327	14
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	seasonal allergic rhinitis	0.620287278383327	14
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	seasonal allergic rhinitis	0.620287278383327	14
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	seasonal allergic rhinitis	0.620287278383327	14
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	seasonal allergic rhinitis	0.581326863490048	9
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Vitiligo	0.417884831049486	32
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	relapsing-remitting multiple sclerosis	0.64736606261308	54
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	relapsing-remitting multiple sclerosis	0.303701503622198	12
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	relapsing-remitting multiple sclerosis	0.64002439670588	53
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	relapsing-remitting multiple sclerosis	0.64372552302434	48
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	relapsing-remitting multiple sclerosis	0.64372552302434	48
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	relapsing-remitting multiple sclerosis	0.655930591244198	144
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	relapsing-remitting multiple sclerosis	0.643752814149123	48
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	relapsing-remitting multiple sclerosis	0.643347103603292	47
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	relapsing-remitting multiple sclerosis	0.643347103603292	47
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	targetBased	326024	350	mucocutaneous lymph node syndrome	0.495035722399972	65
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	acute graft vs. host disease	0.515680643226986	9
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	Myasthenia gravis	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	Myasthenia gravis	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	Myasthenia gravis	0.628049159950515	18
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	Myasthenia gravis	0.628049159950515	18
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	Myasthenia gravis	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	Myasthenia gravis	0.628049159950515	18
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	Myasthenia gravis	0.628049159950515	18
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	autoimmune disease	0.284976181084817	328
Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE)	SIAE	targetBased	369933	2555	autoimmune disease	0.70498382256379	32
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	autoimmune disease	0.26935989249464	558
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	autoimmune disease	0.259092984642321	3018
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	autoimmune disease	0.33909468052582	139
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	autoimmune disease	0.461685404329151	534
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	autoimmune disease	0.461685404329151	534
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	autoimmune disease	0.461685404329151	534
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	autoimmune disease	0.461685404329151	534
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	autoimmune disease	0.461685404329151	534
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	autoimmune disease	0.461685404329151	534
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	targetBased	369953	3080	autoimmune disease	0.267975631196369	285
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	targetBased	217454	1142	autoimmune disease	0.313808795263764	79
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	targetBased	326022	1334	autoimmune disease	0.424809734170857	159
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	autoimmune disease	0.270604544732409	1003
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	targetBased	329153	670	autoimmune disease	0.270604544732409	1003
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	targetBased	72026	352	autoimmune disease	0.270604544732409	1003
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	targetBased	72026	1794	autoimmune disease	0.270604544732409	1003
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	autoimmune disease	0.427740335161443	100
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	autoimmune disease	0.322850001488186	1212
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	autoimmune disease	0.897704362357904	1295
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	autoimmune disease	0.897704362357904	1295
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	autoimmune disease	0.568589520918476	192
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	autoimmune disease	0.568589520918476	192
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	proctitis	0.583175100421059	9
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	proctitis	0.583175100421059	9
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	proctitis	0.583175100421059	9
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	proctitis	0.583175100421059	9
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	proctitis	0.583175100421059	9
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	proctitis	0.583175100421059	9
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	small bowel Crohn's disease	0.286105916237584	14
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	allergic rhinitis	0.485483319847018	22
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	allergic rhinitis	0.485483319847018	22
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	targetBased	290726	671	allergic rhinitis	0.332353881234872	7
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	allergic rhinitis	0.447576648851219	199
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	allergic rhinitis	0.447576648851219	199
qHTS of IL-2 Activators	IL2	targetBased	364617	238	allergic rhinitis	0.320282297274405	152
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	allergic rhinitis	0.535980475306307	47
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pathwayBased	362051	17187	allergic rhinitis	0.386445309864048	181
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	targetBased	304060	10600	allergic rhinitis	0.30110251368226	17
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	pathwayBased	7671	874	allergic rhinitis	0.30110251368226	17
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	pathwayBased	305439	16717	allergic rhinitis	0.30110251368226	17
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	targetBased	73174	1034	allergic rhinitis	0.411026948368507	11
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	allergic rhinitis	0.532859659476675	20
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	allergic rhinitis	0.627077400922343	17
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	allergic rhinitis	0.627077400922343	17
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	allergic rhinitis	0.627077400922343	17
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	allergic rhinitis	0.627077400922343	17
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	allergic rhinitis	0.627077400922343	17
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	allergic rhinitis	0.548658639799238	14
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	allergic rhinitis	0.427563036899599	34
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	lupus nephritis	0.368678188787264	6
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphatic system disease	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphatic system disease	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphatic system disease	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphatic system disease	0.293285626205835	1400
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphatic system disease	0.293285626205835	1400
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	targetBased	325630	216	lymphatic system disease	0.277557010338014	91
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	interleukin 1 receptor-like 1 measurement	0.516816961193787	14
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	interleukin 18 receptor 1 measurement	0.346397165145154	11
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	secondary progressive multiple sclerosis	0.487644718997637	42
Cell-based coincidence reporter assay to measure PMP22 gene transcription in S16 Pmp22-F2sN cells - Primary screen	PMP22	targetBased	42576	834	chronic inflammatory demyelinating polyneuropathy	0.634841225279261	45
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	STAT3 gain of function	0.606952560260641	770
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	STAT3 gain of function	0.606952560260641	770
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	neuroinflammatory disorder	0.428791740822698	18
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	neuroinflammatory disorder	0.428791740822698	18
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	neuroinflammatory disorder	0.428791740822698	18
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	neuroinflammatory disorder	0.395913906802846	7
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	neuroinflammatory disorder	0.395913906802846	7
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	neuroinflammatory disorder	0.412009492152627	161
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	neuroinflammatory disorder	0.412009492152627	161
qHTS for Inhibitors of TGF-b	TGFB1	pathwayBased	403345	4970	inflammatory bowel disease, immunodeficiency, and encephalopathy	0.752376428542243	30
Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation	WEE1	targetBased	217959	2616	neuroinflammatory disorder	0.424632003390909	9
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	neuroinflammatory disorder	0.465852538787439	39
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	neuroinflammatory disorder	0.465852538787439	39
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	neuroinflammatory disorder	0.303641809113339	7
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	targetBased	369953	1596	neuroinflammatory disorder	0.362258189767571	7
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	neuroinflammatory disorder	0.450938815833541	24
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pathwayBased	362051	17187	systemic inflammatory response syndrome	0.297340349354546	203
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	macrophage activation syndrome	0.307196122303397	131
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	psoriasis vulgaris	0.655284149899379	86
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	targetBased	356160	3470	monogenic diabetes	0.443040939126801	18
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	targetBased	356160	1703	monogenic diabetes	0.443040939126801	18
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	monogenic diabetes	0.723854062699688	131
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	monogenic diabetes	0.723854062699688	131
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	hypersensitivity reaction disease	0.268730617640425	213
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	Inflammatory abnormality of the skin	0.296789047816734	55
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	Immunodeficiency	0.374658619756015	36
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	Immunodeficiency	0.507538257966889	8
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Combined immunodeficiency	0.509775695278464	11
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Combined immunodeficiency	0.509775695278464	11
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	Combined immunodeficiency	0.509686858131481	33
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	targetBased	385746	932	Amyotrophic lateral sclerosis	0.411659407127753	675
qHTS of TDP-43 Inhibitors	TARDBP	pathwayBased	403703	7150	Amyotrophic lateral sclerosis	0.42662742198745	2529
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	pathwayBased	45163	203	Amyotrophic lateral sclerosis	0.42662742198745	2529
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	targetBased	217959	923	Amyotrophic lateral sclerosis	0.411250221903632	149
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	neutropenia	0.429115894771016	18
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	hyper-IgM syndrome	0.41140906059619	148
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	allergic asthma	0.305785418457101	20
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	inborn error of immunity	0.567222711159724	483
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	inborn error of immunity	0.567222711159724	483
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	inborn error of immunity	0.260508250524808	558
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	inborn error of immunity	0.35263597806567	286
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	inborn error of immunity	0.323072945633956	978
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	inborn error of immunity	0.323072945633956	978
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	inborn error of immunity	0.321548150235644	156
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	inborn error of immunity	0.309008733126974	490
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	inborn error of immunity	0.309008733126974	490
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	979	allergic disease	0.451288505056579	24
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	pathwayBased	64908	278	allergic disease	0.451288505056579	24
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	allergic disease	0.511316437424948	6
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	allergic disease	0.403052761694357	225
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	allergic disease	0.403052761694357	225
qHTS of IL-2 Activators	IL2	targetBased	364617	238	allergic disease	0.343320178641678	170
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	allergic disease	0.255964635028286	34
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	991	allergic disease	0.554877973171716	8
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	targetBased	335239	695	allergic disease	0.554877973171716	8
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	targetBased	75924	1804	allergic disease	0.518691103234877	71
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	targetBased	73174	1034	allergic disease	0.33358317257055	14
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	allergic disease	0.540851322143723	28
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	allergic disease	0.628446114609922	34
HCS assay for microtubule stabilizers	TUBB	targetBased	195821	1625	allergic disease	0.392468604405345	6
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	targetBased	305610	3878	multiple sclerosis	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	targetBased	305610	1082	multiple sclerosis	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	targetBased	305610	1552	multiple sclerosis	0.645235750885557	44
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	targetBased	343666	1267	multiple sclerosis	0.645235750885557	44
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	targetBased	342084	3260	multiple sclerosis	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	targetBased	305609	3405	multiple sclerosis	0.645235750885557	44
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	targetBased	305600	1644	multiple sclerosis	0.645235750885557	44
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	targetBased	336894	489	multiple sclerosis	0.690530836424373	76
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	targetBased	290355	265	multiple sclerosis	0.284952492325572	8
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	targetBased	86095	1442	multiple sclerosis	0.304265510825839	41
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	targetBased	86095	1151	multiple sclerosis	0.304265510825839	41
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	multiple sclerosis	0.301837416904597	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	multiple sclerosis	0.583926180418581	160
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	targetBased	326888	645	multiple sclerosis	0.645671851693653	110
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	771	multiple sclerosis	0.653518109271019	73
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	targetBased	217959	569	multiple sclerosis	0.653518109271019	73
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	multiple sclerosis	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	multiple sclerosis	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	multiple sclerosis	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	multiple sclerosis	0.511922137474039	26
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	multiple sclerosis	0.511922137474039	26
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	targetBased	356517	1139	multiple sclerosis	0.284450608994791	52
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	targetBased	108286	1415	multiple sclerosis	0.602040251565065	19
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	multiple sclerosis	0.330567104836404	30
Fluorescence polarization assay for PLK1 inhibitors	PLK1	targetBased	97099	518	multiple sclerosis	0.577168330395272	6
qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen	PLK1	targetBased	364065	10181	multiple sclerosis	0.577168330395272	6
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	multiple sclerosis	0.464976182091521	78
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	multiple sclerosis	0.464976182091521	78
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	targetBased	55710	315	multiple sclerosis	0.664837114041353	511
S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity	S100A4	targetBased	352235	501	multiple sclerosis	0.388943152731707	6
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	targetBased	316642	617	multiple sclerosis	0.527972301614307	14
uHTS identification of small molecule modulators of NR3A	GRIN3A	targetBased	339772	8480	multiple sclerosis	0.554511094041346	18
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	pathwayBased	43989	342	multiple sclerosis	0.513718581157192	56
Primary HTS Assay for S1P3 Antagonists	S1PR3	targetBased	169141	462	multiple sclerosis	0.655299992173261	82
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	447	multiple sclerosis	0.657352493094362	83
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	targetBased	96879	207	multiple sclerosis	0.657352493094362	83
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	leukocyte adhesion deficiency 1	0.846366489681156	1155
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	hyper-IgE recurrent infection syndrome 1, autosomal dominant	0.882249492479488	959
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	hyper-IgE recurrent infection syndrome 1, autosomal dominant	0.882249492479488	959
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	immune deficiency disease	0.316021335076101	957
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	immune deficiency disease	0.316021335076101	957
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	Omenn syndrome	0.773255884585553	42
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	hyper-IgM syndrome type 2	0.879623212791959	387
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	graft versus host disease	0.624473599370751	132
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	graft versus host disease	0.329151702280302	47
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	targetBased	359244	2975	graft versus host disease	0.289620981036984	8
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	graft versus host disease	0.530616370782023	24
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	targetBased	343468	734	graft versus host disease	0.287495758286774	32
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	combined immunodeficiency	0.6056619781946	71
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	combined immunodeficiency	0.6056619781946	71
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	combined immunodeficiency	0.317197697603538	6424
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	combined immunodeficiency	0.647259809976761	700
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome	0.894516532057074	815
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome	0.894516532057074	815
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	severe combined immunodeficiency	0.700962625675913	816
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	agammaglobulinemia	0.300066410503025	179
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	agammaglobulinemia	0.300066410503025	179
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	chronic mucocutaneous candidiasis	0.611677577432826	289
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	chronic mucocutaneous candidiasis	0.611677577432826	289
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	hemophagocytic syndrome	0.340446484450425	16
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	leukocyte adhesion deficiency	0.750707304739755	536
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	hyper-IgE syndrome	0.791517184926309	530
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	hyper-IgE syndrome	0.791517184926309	530
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	T-B- severe combined immunodeficiency	0.646206966714383	547
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	targetBased	217454	1142	chronic granulomatous disease	0.707233849788776	336
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	targetBased	359518	300	22q11.2 deletion syndrome	0.413346187350415	9
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	targetBased	335652	1779	22q11.2 deletion syndrome	0.413346187350415	9
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	targetBased	362274	1056	22q11.2 deletion syndrome	0.413346187350415	9
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	targetBased	336308	6862	22q11.2 deletion syndrome	0.413346187350415	9
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	targetBased	357537	806	22q11.2 deletion syndrome	0.413346187350415	9
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	targetBased	339887	1178	22q11.2 deletion syndrome	0.413346187350415	9
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	autoimmune enteropathy	0.300697343647726	276
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	autoimmune enteropathy	0.300697343647726	276
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	targetBased	59788	212	chronic graft versus host disease	0.327543716477058	35
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	immunodeficiency disease	0.281553929492058	479
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	immunodeficiency disease	0.281553929492058	479
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	immunodeficiency disease	0.287801738691034	428
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	immunodeficiency disease	0.287801738691034	428
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	immunodeficiency disease	0.310321407554987	806
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	immunodeficiency disease	0.315004903858155	857
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	immunodeficiency disease	0.315004903858155	857
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	immunodeficiency 69	0.503413308689518	8
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	T-B+ severe combined immunodeficiency	0.515494163057825	40
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	targetBased	339297	1446	anaphylaxis	0.582453837228469	12
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	targetBased	360873	7438	immunodeficiency, developmental delay, and hypohomocysteinemia	0.847171548352911	36
qHTS of Nrf2 Activators	Nrf2 activators	pathwayBased	403871	1243	immunodeficiency, developmental delay, and hypohomocysteinemia	0.847171548352911	36
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Chronic mucocutaneous candidosis	0.898378085302774	825
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Chronic mucocutaneous candidosis	0.898378085302774	825
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	Autosomal dominant hyper-IgE syndrome	0.882882834629081	1250
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	Autosomal dominant hyper-IgE syndrome	0.882882834629081	1250
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	targetBased	67275	2509	Primary hemophagocytic lymphohistiocytosis	0.547474714183054	63
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	targetBased	394050	3624	inflammation	0.286397190264778	13
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	335	inflammation	0.415910845994523	72
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	782	inflammation	0.415910845994523	72
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	99314	390	inflammation	0.415910845994523	72
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	811	inflammation	0.415910845994523	72
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196176	670	inflammation	0.415910845994523	72
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	targetBased	196177	519	inflammation	0.415910845994523	72
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).	TPT1	targetBased	302663	2452	Herpetic encephalitis	0.28838130992472	6
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Susceptibility to viral and mycobacterial infections	0.849381507517208	756
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Susceptibility to viral and mycobacterial infections	0.849381507517208	756
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	Familial cold urticaria	0.798662521910481	38
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	Leukocyte adhesion deficiency type I	0.840099916485533	65
HTS of Smad transcription factor inhibitors	SMAD3	targetBased	88033	251	Familial hemophagocytic lymphohistiocytosis	0.392017533166542	8
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	type II hypersensitivity reaction disease	0.267384674774844	170
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	type II hypersensitivity reaction disease	0.302045298918466	408
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	type II hypersensitivity reaction disease	0.302045298918466	408
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	type II hypersensitivity reaction disease	0.314700577014956	687
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	type II hypersensitivity reaction disease	0.252318308693775	686
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	type II hypersensitivity reaction disease	0.252318308693775	686
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	lymphatic system disease	0.256421443619648	118
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	lymphatic system disease	0.261338183572329	27
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	lymphatic system disease	0.261338183572329	27
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	lymphatic system disease	0.258343187398969	363
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	lymphatic system disease	0.303994030836414	1315
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	lymphatic system disease	0.286395979852275	244
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	lymphatic system disease	0.270951962053554	24
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	lymphatic system disease	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	lymphatic system disease	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	lymphatic system disease	0.307418870150215	258
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	hypersensitivity reaction disease	0.302054926818412	443
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	hypersensitivity reaction disease	0.302054926818412	443
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	targetBased	292323	1836	hypersensitivity reaction disease	0.314702437973755	696
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	targetBased	359207	1189	hypersensitivity reaction disease	0.250619928589118	12
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	targetBased	63676	1938	hypersensitivity reaction disease	0.250619928589118	12
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	targetBased	359207	316	hypersensitivity reaction disease	0.250619928589118	12
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	targetBased	63656	2179	hypersensitivity reaction disease	0.250619928589118	12
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	targetBased	359207	4555	hypersensitivity reaction disease	0.250619928589118	12
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	hypersensitivity reaction disease	0.252347407467467	688
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	hypersensitivity reaction disease	0.252347407467467	688
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	targetBased	217959	2390	Abnormality of the immune system	0.250738061112055	218
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	autoimmune disorder of gastrointestinal tract	0.300515512262878	317
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	autoimmune disorder of gastrointestinal tract	0.300515512262878	317
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	targetBased	128695	1039	autoimmune disorder of gastrointestinal tract	0.252080447239734	669
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	targetBased	127961	1153	autoimmune disorder of gastrointestinal tract	0.252080447239734	669
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	B cell deficiency	0.278059242305738	204
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	B cell deficiency	0.278059242305738	204
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	B cell deficiency	0.293415424309692	203
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	B cell deficiency	0.302045929993097	412
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	B cell deficiency	0.302045929993097	412
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	hyperimmunoglobulin syndrome	0.293054070786579	147
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	hyperimmunoglobulin syndrome	0.302015873224594	392
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	hyperimmunoglobulin syndrome	0.302015873224594	392
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	inborn error of immunity	0.266884082183738	47
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	leukocyte disorder	0.265940944674663	211
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	leukocyte disorder	0.274948506767873	418
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	leukocyte disorder	0.281347845545978	1325
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	leukocyte disorder	0.281347845545978	1325
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	leukocyte disorder	0.293880056330526	368
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	leukocyte disorder	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	leukocyte disorder	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	leukocyte disorder	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	leukocyte disorder	0.293944069536877	1499
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	leukocyte disorder	0.293944069536877	1499
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	leukocyte disorder	0.289127425827789	314
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	leukocyte disorder	0.29708712507018	546
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	leukocyte disorder	0.315033846306356	958
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	leukocyte disorder	0.315033846306356	958
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	immune deficiency disease	0.282900280866123	400
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	immune deficiency disease	0.282900280866123	400
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	immune deficiency disease	0.293434735083632	275
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	immune deficiency disease	0.280530062736223	151
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	immune deficiency disease	0.266884082183738	47
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	immune deficiency disease	0.302049368982857	458
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	immune deficiency disease	0.302049368982857	458
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	non-Langerhans cell histiocytosis	0.303994027521701	1314
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	pathwayBased	193265	3100	syndromic agammaglobulinemia	0.278029312774993	118
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	pathwayBased	359244	3094	syndromic agammaglobulinemia	0.278029312774993	118
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	functional neutrophil defect	0.296879875982787	441
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	primary lymphedema	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	primary lymphedema	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	primary lymphedema	0.307418870150215	258
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	lymphedema	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	lymphedema	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	lymphedema	0.307418870150215	258
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	lymphatic malformation	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	lymphatic malformation	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	lymphatic malformation	0.307418870150215	258
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	targetBased	347933	673	microcephaly, growth restriction and increased sister chromatid exchange	0.312126707883687	1978
Primary qHTS assay for inhibitors of Activation Induced Cytidine Deaminase (AID): AID signal	AICDA_inhibitors	targetBased	90878	289	immunodeficiency disease	0.293439877042445	345
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	immunodeficiency disease	0.326988384067494	13299
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	targetBased	359207	1432	lymphoid system disorder	0.256421443619648	118
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	pathwayBased	70898	707	lymphoid system disorder	0.261338183572329	27
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	pathwayBased	131324	544	lymphoid system disorder	0.261338183572329	27
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	targetBased	57013	201	lymphoid system disorder	0.258343187398969	363
qHTS Assay for NPC1 Promoter Activators	NPC1	pathwayBased	320682	7575	lymphoid system disorder	0.303994030836414	1315
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	lymphoid system disorder	0.286395979852275	244
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	targetBased	194628	267	lymphoid system disorder	0.270955346870825	25
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	targetBased	194152	656	lymphoid system disorder	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	targetBased	194152	1288	lymphoid system disorder	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	targetBased	194152	814	lymphoid system disorder	0.307418870150215	258
uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay	artemis_inhibitors	targetBased	30104	235	familial severe combined immunodeficiency	0.30736672335538	539
qHTS assay for re-activators of p53 using a Luc reporter	TP53	pathwayBased	321427	201	lymphoid system disorder	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54509	528	lymphoid system disorder	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	54513	338	lymphoid system disorder	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	125394	1890	lymphoid system disorder	0.28981872771125	1409
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	targetBased	124022	1156	lymphoid system disorder	0.28981872771125	1409
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Primary immunodeficiency due to a defect in innate immunity	0.308814750112337	560
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Primary immunodeficiency due to a defect in innate immunity	0.308814750112337	560
HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.	ITGB2	targetBased	92518	501	Primary immunodeficiency due to a defect in innate immunity	0.280428462857787	42
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	Primary immunodeficiency due to a defect in innate immunity	0.266507580720034	22
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Genetic susceptibility to infections due to particular pathogens	0.308738055196523	545
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Genetic susceptibility to infections due to particular pathogens	0.308738055196523	545
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	targetBased	322361	619	DNA repair defect other than combined T-cell and B-cell immunodeficiencies	0.321645326286388	6829
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	pathwayBased	195980	5134	Genetic immune deficiency with skin involvement	0.299233459881725	277
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	targetBased	195980	695	Genetic immune deficiency with skin involvement	0.299233459881725	277
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	pathwayBased	194666	1772	Genetic immune deficiency with skin involvement	0.294031557794827	422
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	pathwayBased	194666	1722	Genetic immune deficiency with skin involvement	0.294031557794827	422
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	targetBased	330392	1295	Autoinflammatory syndrome with immune deficiency	0.26595669758817	16

Some of these associations have also gone through clinical trials, as those in the graph below.

graph

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

table